iberdomide + rituximab + gemcitabine + cisplatin + dexamethasone

This is a **combination regimen** of five drugs containing **iberdomide**, **rituximab**, **gemcitabine**, **cisplatin**, and **dexamethasone**. - **Iberdomide** is a cereblon E3 ligase modulator (CELMoD) with immunomodulatory and antineoplastic effects, primarily by targeting cereblon to induce the degradation of transcription factors essential for cancer cell survival and enhancing anti-tumor immunity[1][2][7]. - **Rituximab** is a monoclonal antibody directed against CD20 on B cells, leading to B-cell depletion via antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, and apoptosis. - **Gemcitabine** is a nucleoside analog and antimetabolite that inhibits DNA synthesis, causing cell death in proliferating cells. - **Cisplatin** is a platinum-containing chemotherapeutic that forms DNA crosslinks and induces apoptosis in rapidly dividing cells. - **Dexamethasone** is a synthetic glucocorticoid with potent anti-inflammatory and immunosuppressive actions, commonly used to lessen chemotherapy side effects and as an anti-cancer agent in some hematological malignancies[4][7]. This multi-drug regimen may be considered for treating **relapsed/refractory lymphoma** or multiple myeloma, especially in settings where aggressive, multi-agent chemotherapy is warranted. The specific combination outlined in the query does not correspond to a unique branded regimen, but the individual and dual/triple-drug combinations (such as iberdomide + rituximab or gemcitabine + cisplatin + dexamethasone) have established clinical use in hematologic malignancies[1][2][4].